



June 13, 2018

STERIS Corporation
Anthony Piotrkowski
Senior Regulatory Affairs Manager
5960 Heisley Road
Mentor, Ohio 44060

Re: K181429

Trade/Device Name: CELERITY 20 HP Biological Indicator
Regulation Number: 21 CFR 880.2800
Regulation Name: Sterilization Process Indicator
Regulatory Class: Class II
Product Code: FRC
Dated: May 30, 2018
Received: June 1, 2018

Dear Anthony Piotrkowski:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good

manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Elizabeth F. Claverie -S

For Tina Kiang, Ph.D.
Acting Director
Division of Anesthesiology,
General Hospital, Respiratory,
Infection Control, and Dental Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K181429

Device Name

Celerity 20 HP Biological Indicator

Indications for Use (Describe)

The CELERITY Biological Indicator is used for routine monitoring, and qualification of the Non Lumen, Flexible, Lumen and Fast Non Lumen Cycles of the V-PRO 1, 1 Plus, maX, 60 and maX 2 Low Temperature Sterilizers in healthcare facilities.

When used in conjunction with the VERIFY CELERITY 20 HP Incubator, the CELERITY 20 HP Biological Indicator provides a fluorescent result within 20 minutes.

Type of Use (Select one or both, as applicable)

☐ Prescription Use (Part 21 CFR 801 Subpart D)

☒ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



**510(k) Summary
For K181429
Celerity 20 HP Biological Indicator**

Sponsor Facility

STERIS Corporation
5960 Heisley Road
Mentor, OH 44060
Phone: (440) 354-2600
Fax No: (440) 357-9198

Manufacturing Facility

STERIS Corporation
9325 Pinecone Drive
Mentor, OH 44060
Phone: (440) 392-7800
Fax No: (440) 392-7896

Contact: Tony Piotrkowski
Senior Manager, Regulatory Affairs

Telephone: (440) 392-7437
Fax No: (440) 357-9198
e-mail: tpiotrko@steris.com

1. Device Name

Trade Name: Celerity 20 HP Biological Indicator

Common/usual Name: Biological Indicator (BI, SCBI)

Device Classification: Class II

Classification Name: Indicator, Biological Sterilization Process
(21 CFR 880.2800, FRC)

2. Predicate Device

Celerity 20 HP Biological Indicator, K172752

3. Description of Device

The product is intended to monitor the vapor phased hydrogen peroxide sterilization cycles described in the indications for use. It produces an optical change (signal) that is detected by the STERIS proprietary reader, CELERITY 20 HP Incubator, within 20 minutes to confirm the viability of the biological indicator at the end of a sterilization process. The product consists of *Geobacillus stearothermophilus* spores and a defined nutrient media in a plastic vial. A reporter enzyme, which is produced by the organism, reacts with a fluorogenic substrate within the defined nutrient media to produce a fluorescent moiety.

4. Intended Use/ Indications for Use

The CELERITY Biological Indicator is used for routine monitoring, and qualification of the Non Lumen, Flexible, Lumen and Fast Non Lumen Cycles of the V-PRO 1, 1 Plus, maX, 60 and maX 2 Low Temperature Sterilizers in healthcare facilities.

When used in conjunction with the VERIFY CELERITY 20 HP Incubator, the CELERITY 20 HP Biological Indicator provides a fluorescent result within 20 minutes.

5. Summary of Technical Characteristics

A comparison of technical characteristics are summarized in **Table 5-1**.

Table 5-1. Summary of SCBI Physical Description and Technological Properties

Feature	CELERITY 20 HP BI K181429	CELERITY 20 HP BI Predicate (K172752)	Comparison
Intended Use	The CELERITY Biological Indicator is used for routine monitoring, and qualification of the Non Lumen, Flexible, Lumen and Fast Non Lumen Cycles of the V-PRO 1, 1 Plus, maX, 60 and maX 2 Low Temperature Sterilizers in healthcare facilities. When used in conjunction with the VERIFY CELERITY 20 HP Incubator, the CELERITY 20 HP Biological Indicator provides a fluorescent result within 20 minutes.	The CELERITY Biological Indicator is used for routine monitoring, and qualification of the Non Lumen, Flexible, Lumen and Fast Non Lumen Cycles of the V-PRO 1, 1 Plus, maX, 60 and maX 2 Low Temperature Sterilizers in healthcare facilities. When used in conjunction with the VERIFY CELERITY 20 HP Incubator, the CELERITY 20 HP Biological Indicator provides a fluorescent result within 20 minutes.	Identical
Indicator organism	<i>Geobacillus stearothermophilus</i>	<i>Geobacillus stearothermophilus</i>	Identical
Mechanism of action	An enzyme, which is produced by the organism, reacts with a fluorogenic substrate within the defined nutrient media to produce a fluorescent moiety.	An enzyme, which is produced by the organism, reacts with a fluorogenic substrate within the defined nutrient media to produce a fluorescent moiety.	Identical
Accessories	Automated incubator / reader	Automated incubator / reader	Identical
Viable spore population	1.0 – 4.0 x 10 ⁶ spore/BI	1.0 – 4.0 x 10 ⁶ spore/BI	Identical
Resistance characteristics	Resistance @ 9.1 mg/L H ₂ O ₂ : • <u>D-value</u> > 3 sec • <u>Survival Time</u> ≥ 4 sec • <u>Kill Time</u> ≤ 6 min	Resistance @ 9.1 mg/L H ₂ O ₂ : • <u>D-value</u> > 3 sec • <u>Survival Time</u> ≥ 4 sec • <u>Kill Time</u> ≤ 6 min	Identical
Culture Conditions	55- 59°C, media included in BI, 20-minute incubation time.	55- 59°C, media included in BI, 20-minute incubation time.	Identical
Primary Packaging	Direct inoculum on plastic vial, cap with recovery media.	Direct inoculum on plastic vial, cap with recovery media.	Identical
Process indicator	VERIFY V-PRO Chemical Indicator (K140515); magenta to yellow color change.	VERIFY V-PRO Chemical Indicator (K140515); magenta to yellow color change.	Identical
Label	Single-ply on cap edge	Two-ply on top of cap	Same adhesive and substrate, different format and location
Shelf-life	Currently 7 months Target of 13 months	Currently 7 months Target of 13 months	Real Time Testing Ongoing

6. Summary of Nonclinical Tests

Performance testing to demonstrate substantial equivalence to the predicate has been completed and is summarized in **Table 5-2** below.

Table 5-2. Summary of Non-clinical Testing

Test	Acceptance Criteria	Result
Simulated Use	BI is inactivated when exposed in a worst-case cycle with a worst-case load	No growth of BI

7. Conclusion

The Celerity 20 HP Biological Indicator has met the established performance criteria. The conclusions drawn from the nonclinical tests performed demonstrate the subject device is as safe, as effective, and performs as well or better than the legally marketed predicate device, K172752 Class II (21 CFR 880.2800, Product code FRC).